NU 6027
| CAS No. | 220036-08-8 | Cat. No. | BCP09221 |
| Name | NU 6027 | ||
| Synonyms | NU-6027;NU6027; | ||
| Formula | C11H17N5O2 | M. Wt | 251.29 |
| Description | A cell-permeable, pyrimidine derivative that acts as an ATP-competitive CDK Inhibitor (Ki = 2.5 μM for CDK1, and Ki = 1.3 μM for CDK2), and demonstrates cytostatic properties among a panel of 57 cancer cell lines. Also inhibits ATR kinase (IC50 = 6.7 μM in MCF7 cells), but does not interfere with irradiation-induced autophosphorylation of DNA-PK or ATM. Potentiates a range of DNA-damaging cytotoxic drugs such as hydroxyurea (1.8-fold) and cisplatin (1.4-fold) at 10 μM, but not the anti-mitotic paclitaxel. Attenuates G2/M arrest following DNA damage and inhibits RAD51 focus formation. Shown to be synthetically lethal when DNA single-strand break repair is impaired in PARP-inhibited cells. | ||
| Pathways | Cell Cycle/DNA Damage PI3K/Akt/mTOR | ||
| Targets | ATM/ATR CDK | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.